Back to News
Market Impact: 0.42
CAPR Shareholder Alert: September 28, 2026 Lead Plaintiff Deadline in Capricor Therapeutics, Inc. Securities Class Action
Source: GlobeNewswire
Legal & LitigationHealthcare & BiotechRegulation & LegislationCompany Fundamentals
A securities class action alleges Capricor Therapeutics downplayed the risk that its Phase 3 HOPE-3 trial was functionally unblinded because of a distinctive hypersensitivity-reaction profile. FDA reviewers subsequently flagged the issue, and Capricor shares fell approximately 78.7%, creating substantial litigation and regulatory risk for CAPR.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.82
Ticker Sentiment
CAPR-0.95
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Paramount will need to release way more movies to make this merger work
- Sullivan: Wall Street admits it doesn't know where oil is headed. There's one stock they do agree on
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- We Want This Country to Win Tokenization: SEC's Selway